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Abstract
Glioblastoma is a refractory malignancy with limited treatment options at tumor recurrence. Only a small proportion
of patients survive 2 years or longer with the current standard of care. Gene expression profiling can segregate
newly diagnosed patients into groups with different prognoses, and these biomarkers are being incorporated into a
new generation of personalized clinical trials. Using the experience from recently completed large scale, multi-faceted,
randomized glioblastoma clinical trials, a new clinical trial paradigm is being established to move promising therapies
forward into the newly diagnosed treatment setting. Upcoming trials using the immune check-point inhibitors are an
example of this changing paradigm and these and other immunotherapies have potential as promising new treatment
modalities for newly diagnosed GB patients.
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Introduction
Glioblastoma (GB) is the most common primary brain
malignancy in adults and accounts for 45.6 % of all
primary brain malignancies. GB has an incidence rate of
3.19 per 100,000 and occurs at a median age of
64.0 years, although GB can occur at all ages [1]. The
majority of GBs occur in the cerebral hemispheres,
although brainstem, cerebellar, and spinal cord GBs
rarely occur [2]. The average overall survival (OS) of GB
patients from population series is between 8 and 14 months
[3]. Prognosis of GB can be stratified by clinical features,
with age younger than 50 years, Karnofsky performance
status (KPS) of 70 or better, non-eloquent tumor location,
and maximal extent of resection all associated with im-
proved patient outcomes [4, 5].
The backbone of upfront treatment of GB is maximal
surgical resection and adjuvant radiotherapy to a dose of
6,000 cGy. Upfront treatment often included nitrosoureas
[6], although when added to surgical resection and radio-
therapy modest benefit could only be demonstrated by
meta-analysis [7]. Temozolomide, an oral alkylating agent
with good blood-brain barrier penetration, was developed
in the 1990s and showed benefit in the recurrent setting
in GBs and recurrent anaplastic gliomas gaining approval
for this indication [8]. The randomized phase III, EORTC-
NCIC trial 22981/26981, published in 2005, established
the current standard of care, including maximal surgical
resection followed by radiotherapy with concurrent and
adjuvant temozolomide, and demonstrated improved OS
of 14.6 versus 12.1 months and increased proportion of 2-
year and 5-year survivorship compared to radiotherapy
alone [9, 10].
With approximately 5 % of patients surviving 5 years
from diagnosis, additional treatment options for newly
diagnosed GB patients are needed [10]. Further im-
provement of upfront treatment of GB is important
as approved treatment options for tumor recurrence,
including cytotoxic chemotherapy agents, such as ni-
trogen mustards, bevacizumab, and tumor-treatment
fields, are of limited efficacy [11–13]. For example,
approximately 20 % of patients with recurrent GBs treated
with lomustine (CCNU) are alive and progression-free
6 months after starting treatment. Bevacizumab, a
monoclonal antibody against vascular endothelial
growth factor (VEGF), is approved by the US Food and
Drug Administration (FDA) for use in recurrent GB
based on a relatively high rate of radiographic response
and improvement in progression-free survival, but with
no evidence to date of a significant improvement in
overall survival [14].
* Correspondence: brett.j.theeler.mil@mail.mil
1Department of Neurology and John P. Murtha Cancer Center, Walter Reed
National Military Medical Center, 8901 Wisconsin Avenue, Building 19,
Bethesda, MD 20889, USA
Full list of author information is available at the end of the article
© 2015 Theeler and Gilbert. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Theeler and Gilbert BMC Medicine  (2015) 13:293 
DOI 10.1186/s12916-015-0536-8
Prognostic biomarkers and gene expression profiling
Prior clinical observations noted that secondary GBs,
defined as GBs arising from grade II and III infiltrating
gliomas, had improved outcomes compared to primary
GBs, or those tumors that arise as GBs de novo. Primary
and secondary GBs were noted to have different gene
mutations and to over-express different extra- and intra-
cellular proteins; for example, epidermal growth factor
(EGFR) over-expression is more common in primary
GBs [15]. Although, when controlling for age and other
patient-related factors, the biologic markers of primary
and secondary GBs, including EGFR over-expression, are
not independent prognostic biomarkers.
The DNA repair enzyme O6-methylguanine methyl-
transferase (MGMT) repairs O6- methylguanine adducts.
Hypermethylation of the MGMT gene promoter leads to
silencing of MGMT expression. This mechanism can
counteract the effects of temozolomide which alkylates
the O6 position on guanine, resulting in futile activation
of the mismatch repair system and ultimately apoptosis
[16]. In addition to establishing the standard of care, the
EORTC-NCIC trial retrospectively demonstrated that
patients with MGMT promoter methylation have an
improved prognosis compared to those patients with
unmethylated promoter regions [17]. In both the EORTC-
NCIC trial and another single-institution retrospective
study, newly diagnosed GB patients with MGMT pro-
moter methylation treated with upfront radiotherapy
alone had improved survival outcomes, suggesting that
MGMT promoter methylation may be prognostic re-
gardless of upfront treatment; however, patients with
MGMT promoter methylation treated with temozolo-
mide had the best overall survival outcomes in the
EORTC-NCIC trial [9, 18].
Given the antagonistic mechanisms of MGMT-mediated
DNA repair and temozolomide, it was hypothesized that
higher doses of temozolomide may overcome the DNA
repair capacity of MGMT [19]. This hypothesis led to the
design of RTOG 0525, a randomized phase III trial com-
paring dose-intense temozolomide (75–100 milligrams per
meter squared taken on days 1 to 21 of a 28-day cycle) ver-
sus standard dose temozolomide (150–200 milligrams per
meter squared on days 1 to 5 of a 28-day cycle). This trial
included prospective tissue collection and stratification of
both groups by clinical prognostic factors and MGMT pro-
moter methylation. No benefit of dose-intense temozolo-
mide was seen overall, or in the subgroups of MGMT
hypermethylated or unmethylated patients. RTOG 0525
confirmed the prognostic significance of MGMT promoter
methylation [20]. While an improved prognosis for newly
diagnosed patients with MGMT promoter methylation
treated with the EORTC-NCIC regimen is established,
there is not an alternative regimen for newly diagnosed GB
patients with unmethylated MGMT promoters otherwise
eligible to receive the EORTC-NCIC regimen. Outside of a
clinical trial, it is the authors’ opinion that all patients with
a KPS of 70 or greater and an age of 65 years or less should
receive the EORTC-NCIC regimen regardless of MGMT
promoter methylation status.
As indicated above, age is an important prognostic
factor [4]. GB patients over the age of 65 years and those
patients with a KPS less than or equal to 60 represent a
clinically important group of patients that develop sig-
nificant toxicity, and there is no prospective evidence of
significant benefit from the EORTC-NCIC regimen in
these patients. In two retrospective studies of newly
diagnosed GB patients aged 65 years and older, including
291 and 237 GB patients respectively, patients with a
good performance status (KPS 70 or greater) and a max-
imal tumor resection significantly benefitted from the
EORTC-NCIC regimen [21, 22]. The Nordic trial ran-
domized patients aged 60 years and older to standard
radiotherapy (60 Gy in 30 fractions), hypofractionated
radiotherapy (34 Gy in 10 fractions), and standard adju-
vant dosing of temozolomide, and demonstrated that
hypofractionated radiotherapy and standard dose temo-
zolomide alone were associated with better outcomes in
patients over the age of 70 years compared to standard
radiotherapy [23]. In the ANOCEF phase II trial, pa-
tients aged 70 years or older and patients with a KPS of
less than 70 were treated with temozolomide, 150–200
milligrams per meter squared for 5 days every 28 days
until disease progression. The ANOCEF trial demonstrated
improved survival outcomes compared to historical out-
comes for supportive care alone [24]. In the ANOCEF trial
and the retrospective studies of elderly GB patients refer-
enced above, MGMT promoter methylation was associated
with superior survival outcomes [21, 22, 24]. The NOA-08
was a randomized phase III trial comparing dose-intense
temozolomide versus standard radiotherapy in patients
over the age of 65 years and those with a KPS greater than
or equal to 60 [25]. This trial demonstrated prospectively
the importance of MGMT promoter methylation in eld-
erly and poor performance status patients as those with
MGMT promoter methylation showed a statistically sig-
nificant benefit of temozolomide and those patients with
unmethylated gene promoters benefited from radiother-
apy. Thus, MGMT promoter methylation can identify a
group of patients with an improved prognosis and is pre-
dictive of overall survival with temozolomide treatment in
elderly and poor performance status GB patients. An on-
going international randomized phase III trial, including
multiple cooperative groups, randomized GB patients
aged 65 years and over to a 3-week course of hypofractio-
nated radiotherapy with concurrent and adjuvant temozo-
lomide versus hypofractionated radiotherapy alone
(NCT00482677). Currently, the optimal treatment for eld-
erly GB patients should include consideration of KPS,
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extent of tumor resection, and presence or absence of
MGMT promoter methylation, and ideally should be de-
cided in a multi-disciplinary setting.
Initial efforts in genome-wide sequencing and muta-
tional analysis found genes previously associated with
GB and other cancers, such as PTEN, EGFR, P53, and
PIK3CA, mutated in GBs [26, 27]. However, there were
some surprising findings, particularly the discovery of
isocitrate dehydrogenase 1 (IDH1) mutations in 10 of
105 GBs [26]. In a larger study of primary brain tumors,
IDH1 mutations were found in the majority of World
Health Organization (WHO) grade II and III infiltrating
astrocytic and oligodendroglial tumors. IDH1 mutations
were found in the majority of secondary GBs, and were
nearly absent in primary GBs [28]. IDH1 mutant GBs
have unique clinical, radiologic, and molecular charac-
teristics. IDH1 mutant GBs are more likely to be front-
ally located and to be non-enhancing on contrast MRI
studies [29]. Mutant IDH1 protein results in neomorphic
enzymatic activity and over-expression of an abnormal
cellular metabolite, 2-hydroxyglutarate (2-HG). This me-
tabolite can be detected on MR spectroscopy, and pro-
vides promise as a novel imaging biomarker for future
interrogation as a means of tracking treatment response
and tumor progression [30, 31]. Most importantly, IDH1
mutant GBs have an improved prognosis compared to
IDH1 wild-type tumors. IDH1 mutations are present in
only 5–10 % of GBs overall, and the average OS for
IDH1 mutant GBs is 3 years or longer compared to just
over 14–16 months for wild-type tumors [32–34]. In a
clinical trial setting it is important to define this patient
population within the study cohort given the improved
survival. Failure to identify patients, particularly in small
clinical trials, could lead to misleading results. The ma-
jority of IDH1 mutant high-grade gliomas also have
MGMT promoter methylation, and IDH1 mutation is a
stronger prognostic biomarker than MGMT promoter
methylation [32–35]. Combined analysis of IDH muta-
tion and MGMT promoter methylation may improve
prognostication over analysis of either biomarker alone,
although the prognostic significance of MGMT pro-
moter methylation may be more significant in IDH1
wild-type tumors [35, 36].
The Cancer Genome Atlas (TCGA) and others have
used high-throughput sequencing techniques, such as
DNA microarray technology, to evaluate large groups of
GBs. These studies have defined three or four different
subtypes of glioblastomas defined by their gene ex-
pression profiles and gene promoter region methyla-
tion signatures [37–39]. The TCGA subclasses include
proneural, neural, classical, and mesenchymal, and are
named based on the functions of the over-expressed
genes in each subclass [38]. Evaluating DNA promoter
methylation, specifically CpG island methylation
pattern, an analysis of GBs in the TCGA found a dis-
tinct subset of GBs with CpG island hypermethylation
of gene promoter regions, termed the CpG island
methylator phenotype (G-CIMP). Nearly all the G-
CIMP tumors have IDH1 mutations and a proneural
pattern of gene expression, and have an improved
prognosis [39]. This distinct subgroup of GBs, with a
G-CIMP phenotype and IDH1 mutation, represent
only 5–10 % of GBs in total. By contrast, GBs with a
mesenchymal gene expression pattern have inferior
survival outcomes with an average OS of 12 months or
less and make up a much larger proportion, approxi-
mately 30 %, of GB patients.
Studies using a genome-wide approach have identified
additional mutations that may be important in under-
standing tumor biology, refining prognostic groups, and
which may eventually guide use of targeted therapeutics.
Multiple studies have reported oncogene and tumor sup-
pressor genes frequently mutated in other cancers, in-
cluding PTEN, TP53, PIK3CA, PIK3R1, NF1, RB1, as
well as amplification of the PDGFR1A and EGFR recep-
tor tyrosine kinases [40]. Activation of the PI3K/Akt/
mTOR and RAS-MAPK pathways are common alter-
ations in GB, and it is worth noting the lack of success
to date using targeted therapeutics modulating these
pathways in newly diagnosed and recurrent GB. The ma-
jority of secondary glioblastomas have IDH1 and TP53
mutations, and serve to mark their evolution from
WHO grade II and III lower grade gliomas which share
these mutations [32]. Recently, it was discovered that
most IDH1 mutant glioblastomas also have ATRX muta-
tions. IDH1 and ATRX mutations are mutually exclusive
from the genetic events that typically occur in primary
(or de novo) GBs, such as EGFR gene amplification and
loss of PTEN function [41]. Increased activation of tel-
omerase reverse transcriptase (TERT) is present in most
human cancers and allows for telomere maintenance
and avoidance of senescence. TERT is among the most
commonly mutated genes in GB and further study of the
prognostic significance of TERT mutations is war-
ranted, and TERT may provide a target for therapeutic
development [42–44].
Finally, rare and recently reported genetic events have
been found in GB, which may lend themselves to treat-
ment with currently available targeted agents. These mu-
tations include point mutations in the BRAF gene, BRAF
V600E and V600K. BRAF V600E mutations are present
in a small minority, fewer than 2 % of GBs, but identifi-
cation may be important as vemurafenib or dabrafenib,
approved for use in metastatic melanoma, may be poten-
tial treatments [45]. A recent report found that over
40 % of BRAF V600E mutated, non-melanoma cancers
responded to treatment with vemurafenib, and this in-
cluded three out of four anaplastic pleomorphic
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xanthoastrocytomas (a rare primary CNS neoplasm)
[46]. Unique gene fusions have been discovered in
many cancers to date, and GB is no exception as the
recently described FGFR-TACC gene fusion produces a
fusion protein with oncogenic activity. While FGFR-
TACC fusions occur in only 3 % of GBs, study of FGFR
inhibition in these patients warrants consideration [47].
The biologic and prognostic importance of these gene
expression studies underscore the opportunity to design
clinical trials in molecularly defined groups of newly di-
agnosed GB patients. In the future, the IDH1 mutant,
G-CIMP subtype may be excluded from some clinical
trials given their improved prognosis with current stand-
ard treatment. Likewise, designing clinical trials targeting
a particular oncogene or tumor suppressor gene muta-
tion enriched in a specific subset of newly diagnosed GB
patients, for example NF1 mutations in mesenchymal
GBs, may allow for more efficient trial designs with a
higher likelihood of success. A significant challenge for
future trial design lies in the sub-dividing of an already
rare tumor into smaller groups.
There is mounting evidence that a subset of IDH1
wild-type WHO grade II and III astrocytic and mixed
gliomas have similar gene expression profiles to GBs,
and have inferior survival outcomes compared to other
tumors of similar WHO grade and histology [34, 48].
One large retrospective study demonstrated that IDH1
wild-type anaplastic astrocytomas had inferior survival
outcomes to IDH1 mutant GBs [34]. Whether these
lower grade tumors should be treated similar to GBs
with the EORTC-NCIC regimen has not been sys-
tematically studied. Designing specific clinical trials
for these patients or including them in the GB clinical trials
is under discussion.
GBs can be molecularly stratified at diagnosis into
subgroups using IDH1 mutation status, MGMT pro-
moter methylation, and gene expression signature (Fig. 1)
[33]. This has prognostic significance and impacts
counseling of patients and families on prognosis. Testing
for IDH1 mutation by immunohistochemistry, IDH1 and
2 mutation testing by polymerase chain reaction, and
commercial testing of MGMT promoter methylation are
widely available. Conversely, gene expression profiling is
not currently available outside of a research setting.
Practically, and at the current time, the treatment of
newly diagnosed patients does not change based on the
presence or absence of these prognostic biomarkers.
Changing the current clinical trial paradigm
Since the establishment of the standard of care in 2005,
a number of phase II clinical trials were completed in
patients with newly diagnosed GB. These trials added
various cytotoxic, targeted, biologic, or immunothera-
peutic agents to the standard temozolomide regimen.
One important lesson from these trials is the necessity
of a control arm in order to interpret results [49]. In
single-arm, phase II clinical trials in newly diagnosed GB
patients, a modest improvement over the EORTC-NCIC
trial was noted with various combination therapies, with
median OS ranging from 15.1 to 21.2 months (compared
to 14.6 months) [49–51]. Patients participating in phase
II clinical trials at large institutions may be patients with
clinical features resulting in a better prognosis, or per-
haps a higher proportion of these patients have favorable
molecular features, such as IDH1 mutations and/or
MGMT promoter methylation.
Dose-intense temozolomide and bevacizumab have
both showed promise in single-arm studies, and demon-
strated strong pre-clinical evidence supporting their po-
tential efficacy in newly diagnosed GB [50, 51]. As
previously discussed, RTOG 0525 showed no advantage
of dose-intense temozolomide, but did show increased
treatment-related toxicity in the dose-dense temozolo-
mide arm [20]. The international, phase III CENTRIC
study tested the addition of cilengitide, an alphavbeta3
and alphavbeta5 integrin inhibitor, to the EORTC NCIC
Fig. 1 Frequency, overlap, and relative survival of glioblastomas (GBs) (includes GB and all GB variants including gliosarcoma) based on molecular
profile. Relative frequency of G-CIMP status, gene expression profiles, IDH1 mutation, and MGMT promoter methylation in GBs. IDH1 mutation and G-CIMP
are depicted as discrete categories, while gene expression and MGMT methylation status are depicted as a continuum. GBs with a proneural
gene expression profile and IDH1 mutations cluster almost exclusively within G-CIMP GBs, and have improved clinical outcomes (left side).
Mesenchymal GBs are exclusively non-G-CIMP and IDH1 wild-type, and have inferior clinical outcomes. G-CIMP, CpG island methylator phenotype;
IDH1 mut, isocitrate dehydrogenase 1 gene mutation; IDH1 wt, isocitrate dehydrogenase 1 wild-type gene. Adapted from Theeler BJ et al. [33], with
permission from Wolters Kluwer Health, Inc.
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regimen in newly diagnosed GB patients with MGMT pro-
moter methylation. The parallel, randomized phase II CORE
study tested cilengitide plus standard treatment in newly di-
agnosed patients with unmethylated MGMT promoters.
Despite promising pre-clinical evidence, neither study
showed an improvement in OS when adding cilengitide to
standard treatment [52, 53]. In a recent development, a
treatment device delivering low-intensity, alternating elec-
trical fields, or tumor treatment fields, called the Optune™
system, has gained FDA approval for newly diagnosed
glioblastoma based on the results of an interim analysis
of the EF-14 randomized phase III clinical trial (http://
www.fda.gov/NewsEvents/Newsroom/PressAnnounce-
ments/ucm465744.htm). The publication of this study is
awaited to evaluate the place of this treatment modal-
ity in newly diagnosed GB patients.
Bevacizumab gained approval for use in recurrent GB in
2009. Despite a lack of definitive evidence that combining
bevacizumab with temozolomide enhanced response, and
conflicting evidence from single-arm studies combining
these agents in the upfront treatment of GB [51, 54], beva-
cizumab was being incorporated into the upfront treatment
of GB at some academic institutions and in the community.
In this backdrop, two large randomized, double-blinded
phase III clinical trials, RTOG 0825 and AVAglio, random-
ized newly diagnosed GB patients to either chemoradiation
with temozolomide plus bevacizumab or temozolomide
plus placebo [55, 56]. Neither trial demonstrated a
benefit in OS. AVAglio demonstrated a progression-
free survival advantage, while RTOG 0825 did not
due to differences in the predetermined statistical
model. In the RTOG 0825 study, prospective deter-
mination of MGMT promoter methylation status and
a 9-gene expression panel (previously shown to be
prognostic in GB [57]) were used to stratify patients
and for subsequent subgroup analyses. However, no
subgroup of patients could be identified that specific-
ally benefited from the combination treatment. RTOG
0825 also demonstrated that patients treated in the
bevacizumab arm had increased treatment-related tox-
icity and inferior scores on symptoms, quality of life,
and neurocognitive measures. In a retrospective, sub-
group analysis of patients in the AVAglio study, those
patients who had tumors which were both IDH1
wild-type and had a proneural pattern of gene expres-
sion may have derived survival benefit from the
addition of bevacizumab [58]. The proneural subgroup
accounts for approximately 25–30 % of newly diagnosed
GBs and prospective confirmation of the benefit of up-
front bevacizumab in this group of patients is
needed. Additional studies of the tumor tissues and
patient data collected from these trials are ongoing.
Testing new treatments in patients with recurrent
glioblastoma then moving those with an “efficacy signal”
to the newly diagnosed setting requires re-evaluation.
There have been a paucity of agents tested in the recur-
rent setting that have been deemed worthy of testing as
frontline treatment. Recurrent GB is a refractory disease,
and the patients often have a poor performance status and
overall health, particularly when compared to newly diag-
nosed patients. The tumors are often large and unresect-
able, with significant requirements for corticosteroid
treatment to control cerebral edema. Perhaps most im-
portantly, overall the response rate and relative efficacy of
therapies in recurrent GB is modest, and it is often diffi-
cult to demonstrate efficacy statistically even in agents
with significant promise pre-clinically. For example,
cediranib, a VEGF-targeted tyrosine kinase inhibitor,
had strong pre-clinical, radiographic, and biomarker
data to support its use in GB. But cediranib failed to dem-
onstrate benefit over CCNU in a well-designed phase III
trial in recurrent GB [11], slowing the development of a
potentially promising agent in newly diagnosed GB.
Tumors at recurrence are different from the primary
tumor, as treatment with radiotherapy, cytotoxic chemo-
therapy, contributes to genetic and biologic changes that
allow the primary tumor to overcome the host micro-
environment and immune system. There is evidence that
temozolomide-induced damage to the DNA mismatch
repair system results in a hypermutated phenotype with
further deficiency in mismatch repair [59]. In one pre-
clinical study comparing primary and recurrent tumors,
temozolomide-treated WHO grade II astrocytomas had
mutations in key intracellular signaling pathways, which
were not present in the primary tumor and could mediate
treatment resistance to cytotoxic and targeted therapeutic
agents [60]. Additionally, some GBs with proneural gene
expression undergo a transition to a mesenchymal pattern
of gene expression at recurrence, similar to that reported
for epithelial cancers [37]. Selecting therapies effective,
or ineffective, at tumor recurrence may not predict ef-
fectiveness in newly diagnosed patients due to acquired
differences between newly diagnosed and recurrent tumors.
Immune checkpoint inhibitors: a new approach to trial
design and treatment of newly diagnosed glioblastoma
The success of immunotherapeutics in previously refrac-
tory systemic solid malignancies, particularly metastatic
melanoma, has led to significant interest in testing similar
therapeutic strategies in glioblastomas. A variety of ap-
proaches are currently being tested in GB clinical trials,
including peptide- and tumor-based vaccine strategies,
oncolytic virotherapy, and adoptive immune strategies,
such as autologous infusions of activated T cells [61, 62].
Recurrent GB is a significant challenge for any thera-
peutic strategy, including immunotherapeutic approaches.
Recurrent GB occurs after patients have undergone radio-
therapy and multiple cycles of cytotoxic chemotherapy,
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and in addition corticosteroids are often required to treat
cerebral edema resulting in relative immune suppression
in many patients. Temozolomide chemotherapy can de-
crease CD4 T lymphocytes, and patients with reduced
CD4 counts have worse clinical outcomes [63]. The re-
lationship between temozolomide-induced lymphopenia
and its effect on OS appears to be complex in studies
testing vaccination strategies in newly diagnosed glioblast-
oma patients. In a single-arm study of rindopepimut,
temozolomide-induced lymphopenia was associated with
improved cellular and humoral immune responses [64],
and in another single-arm phase II study testing an au-
tologous formalin-fixed tumor vaccine, patients with
grade 3 lymphopenia had improved survival outcomes
compared to patients with grade 4 or grade 0–2 lympho-
penia [65]. Recurrent GBs may be large and unresectable
and pose a significant challenge for any systemic therapy,
but may be particularly challenging for immune therapies
which need to access an already hostile tumor micro-
environment. GBs have decreased expression of major
histocompatibility complex (MHC) class I antigen and
immune-suppressive proteins, such as IL-10 and trans-
forming growth factor beta, are secreted in the tumor
microenvironment [61]. Additionally, the potential risk
for immune-related inflammation (pseudoprogression,
discussed subsequently) may be more problematic in
the recurrent setting.
Dendritic cell (DC) vaccine strategies using autologous
tumor lysates or common tumor antigens have been
tested in early-phase clinical trials in newly diagnosed
glioblastoma patients [66, 67]. This methodology appears
to be feasible and safe. Changes in regulatory T cells and
CTLA-4 in the systemic circulation correlates with clinical
activity, and may provide a means of monitoring thera-
peutic response [68]. Albeit in uncontrolled, single-arm
studies with small numbers of patients, impressive overall
median survival rates of 31.4–38.4 months have been ob-
served in newly diagnosed GB patients. Methods to boost
the immune responses, such as tetanus toxoid, or with
chemokines, such as CCL3, may increase immunogenicity
and thereby improve outcomes with DC vaccines in GB
patients [69]. Controlled studies, such as the ongoing ran-
domized phase III study using the autologous dendritic
cell vaccine, DCVax-L (NCT00045968), are needed to
clarify the efficacy of this promising therapeutic strategy.
Gliomas express unique antigens, such as HER-2,
TRP-2, gp100, MAGE-1, IL-13 alpha 2, and AIM-2, and
the ICT-107, an autologous DC vaccine, has been de-
veloped against these antigens [67, 70]. As discussed
above, the phase I results of this study were promising
(median OS of 38.4 months) [67], and the phase II trial
has been completed and the results are forthcoming.
Heat shock proteins (HSPs) are expressed during times
of cellular and environmental stress, and an autologous
HSP-96 peptide complex vaccine has been developed
for glioblastoma [70]. A single-arm phase II study has
been completed in newly diagnosed GB patients and the
results have not yet been published (NCT00905060). In
addition to their prognostic and biologic significance, IDH
mutations may be a tumor-specific target for immuno-
therapeutics. In a recent study, an immune response
generated against unique epitopes expressed on IDH1
mutated gliomas was successful in a mouse model using a
peptide-based vaccine [71].
EGFR variant III (EGFRvIII) is the most common mu-
tation of the EGFR gene in glioblastoma, is present in
25–30 % of GB patients, and is absent in normal tissue
[72]. EGFRvIII mutations are associated with poor long-
term survival and are mutually exclusive with IDH mu-
tations and G-CIMP gene expression [73, 74]. An EGFRvIII
vaccine, called rindopepimut, is a peptide-based vaccination
which targets the unique, tumor-specific antigen created by
the in-frame deletion of the EGFRvIII gene. Promising re-
sults were reported from three phase II trials which added
rindopepimut to standard therapy in newly diagnosed GB
patients with an EGFRvIII mutation. The median OS was
21.8–23.6 months in these single-arm studies [64, 73, 75].
The randomized, phase III, ACT IV clinical trial test-
ing the addition of rindopepimut to radiotherapy and
temozolomide in EGFRvIII mutated, newly diagnosed
GB patients has completed enrollment and these re-
sults are anxiously awaited.
The FDA approval of the immune checkpoint inhibi-
tors, ipilimumab, pembrolizumab, and nivolumab, in
metastatic melanoma has led to significant interest in
rapid development of clinical trials in GB. Ipilimumab, a
humanized IgG1 monoclonal antibody against cytotoxic
T lymphocyte antigen (CTLA-4), has demonstrated
durable responses and a significant improvement in OS
in metastatic melanoma [76]. Perhaps more importantly
as it pertains to GB, it has shown promising activity in
patients with melanoma brain metastases without sig-
nificant central nervous system (CNS) toxicity [77].
The other checkpoint inhibitors, pembrolizumab and
nivolumab, are humanized monoclonal antibodies against
programmed cell death 1 (PD-1), and are approved for use
in metastatic melanoma [78, 79]. Dacarbazine, a cytotoxic
chemotherapeutic agent with a similar mechanism to
temozolomide, was combined with ipilimumab and
combination treatment, and had improved outcomes
compared to dacarbazine alone in metastatic melan-
oma [80]. The sequencing and combination of CTLA-
4 and PD-1 blockade is ongoing in clinical trials in
melanoma, with results suggesting that combination
therapy is more effective but with more treatment-
related toxicity [81].
In a study using an immunohistochemical assay, 88 % of
newly diagnosed GBs had robust and diffuse expression of
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PDL-1, the ligand of PD-1. This rate of expression is
relatively high compared to other cancers, including
melanoma. In this same study, PDL-1 expression was
enriched in GBs with mesenchymal gene expression,
the subset of GBs which have the worse survival outcomes
[82]. In a recent study analyzing PDL-1 expression using
both immunohistochemistry and flow-cytometry, PDL-1
expression was reported in 61 % of patients, but the me-
dian percentage of cells expressing PDL-1 was 2.77 % with
a wide range (0–86.6 %) [83]. Whether expression of
PDL-1 on a small sub-population of GB cells will correlate
with treatment efficacy will be an important determination
in early-phase clinical trials. PDL-1 expression appears to
correlate with worsened survival outcomes [83], and the
expression of PDL-1 in the majority of GBs provides
strong rationale for ongoing clinical trials.
Studies are currently being conducted in recurrent GB
using the checkpoint inhibitors, including nivolumab,
pembrolizumab, and ipilimumab. The CheckMate 143
trial (NCT02017717) is a randomized phase II trial testing
nivolumab alone, nivolumab plus ipilimumab in two dif-
ferent treatment arms versus bevacizumab as an active
comparator in recurrent glioblastoma. In another ran-
domized phase II trial, pembrolizumab is being tested
alone and in combination with bevacizumab in recurrent
glioblastoma (NCT02337491). However, whether a lack of
efficacy in recurrent GB or even increased toxicity will be
similarly predictive of outcomes in the newly diagnosed
setting is questionable, and in our opinion should not pre-
clude or delay development of trials testing checkpoint in-
hibitors in newly diagnosed patients. A randomized phase
II/III trial testing combinations of temozolomide, ipilimu-
mab, nivolumab, and placebo in four different treatment
arms to test whether CTLA-4 blockade alone, PD-1 block-
ade alone, or a combination of both, improve outcomes in
addition to standard upfront treatment is currently open
and accruing patients (NCT02311920, Fig. 2). This study
is designed to take the best experimental arm forward into
a fully-powered, phase III, placebo-controlled clinical trial.
A phase I/II trial with pembrolizumab and temozolo-
mide in newly diagnosed patients is open and accruing
patients (NCT02530502). Additional strategies include
adding checkpoint inhibitors to tumor vaccines to in-
crease the immune response; and the upcoming AVeRT
Fig. 2 Example of a next generation phase II/III clinical trial for newly diagnosed GB. Patients are randomized after stratification by presence or
absence of MGMT promoter methylation (MGMT), clinical factors (recursive partitioning analysis or RPA), and molecular features (gene expression
profile or MCP). All patients receive standard temozolomide (TMZ) chemotherapy on days 1 to 42 during radiotherapy and on days 1 to 5 of 28-day cycles
during adjuvant treatment. Patients will also receive a combination of placebo, ipilimumab (Ipi), or nivolumab (Nivo) in four treatment arms. A “pick the
winner” trial design will be used during phase II to move the most efficacious treatment arm forward into a larger phase III clinical trial. A combination of
OS, treatment-related toxicity, neurocognitive function (NCF), and symptom burden will be used to pick the best treatment (arms). Figure was created for
this manuscript by the authors
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trial is a phase I/II study adding nivolumab to the DC
vaccine in recurrent high grade gliomas testing this
strategy (NCT02529072).
This is not to suggest that upfront trials using check-
point inhibitors will not be challenging. Systemic toxicity
will need to be closely monitored and include auto-
immune adverse events, including colitis, endocrinopa-
thies, and dermatologic manifestations [76]; peripheral
nervous system toxicity such as Guillain-Barré syndrome
and myasthenia gravis have been reported [84]. CNS
toxicity, including transverse myelitis, and inflammation
of brain parenchyma (in the absence of brain metastasis)
have also been reported in the treatment of metastatic
melanoma with checkpoint inhibitors [84, 85].
Pseudoprogression, operationally defined as reversible
radiographic and clinical worsening due to the effects of
treatment, typically radiation therapy and temozolomide,
is now well recognized. It occurs in 20–30 % of glio-
blastoma patients after radiation therapy and temozolo-
mide, and usually occurs within 6 months of combined
temozolomide and radiotherapy [86]. Pseudoprogression
can be difficult to differentiate from tumor progression
on standard MRI sequences, advanced MRI sequences,
including MR spectroscopy and MR perfusion scans,
and even pathologic differentiation can be difficult
[87–89]; see Fig. 3 for a typical example of pseudopro-
gression in a GB patient. Pseudoprogression has been
observed in patients with CNS metastasis from meta-
static melanoma treated with ipilimumab [90], and in
day-to-day practice can make the interpretation of response
to radiotherapy and checkpoint inhibitors difficult. When
combining checkpoint inhibitors, or other immunother-
apeutic agents, with standard upfront therapy, rates of
pseudoprogression may be increased, the typical inter-
val during which pseudoprogression occurs may change
or be prolonged, and differentiating pseudoprogression
from true tumor progression may become an even
more vexing problem. Response Assessment in Neuro-
Oncology (RANO) guidelines have been developed to
help standardize clinical and radiographic assessment
in neuro-oncology clinical trials [91]. The RANO effort
has been expanded to include immunotherapies, so-
called iRANO criteria, to help with the standardization
of interpretation of clinical and imaging assessment in
immunotherapy trials [92]. Specific immune-related re-
sponse criteria (iRANO) are needed for numerous rea-
sons as mentioned previously, including an expected
prolonged time from therapy initiation to immunologic
Fig. 3 Example of imaging and pathologic features of pseudoprogression in a glioblastoma patient 4 months after completing chemoradiation. a Medial,
right frontal lobe enhancing mass which was completely resected due to concern for tumor recurrence. Pathology revealed treatment-related necrosis,
hyalinized blood vessels, and b gliosis (hematoxylin and eosin stain), and a small amount of residual tumor which was not mitotically active (not shown).
Figure was created for this manuscript by the authors
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response, the potential for radiographic worsening ini-
tially meeting criteria for progressive disease which may
then improve in responders, and the potential for con-
tinuing therapy with stable disease or relatively small or
otherwise insignificant disease progression in treatment
responders [92]. Management of the typical autoimmune
complications of checkpoint inhibitors, and determining
management strategies for CNS toxicities, will become an
important part of ultimately incorporating these therapies
into clinical practice.
Conclusions
Glioblastoma is a refractory malignancy with limited
treatment options at tumor recurrence. The standard of
care for GB, including maximal resection, radiotherapy,
and adjuvant temozolomide is currently recommended
for all patients but only a small proportion of patients
survive 2 years or longer. IDH1 mutation, MGMT pro-
moter methylation, and gene expression profiling can
segregate newly diagnosed glioblastoma patients into
groups with different prognoses. While all newly diag-
nosed GB patients currently receive the same standard
treatment, these biomarkers are being incorporated into
a new generation of personalized clinical trials. The
rapid translation of immune checkpoint inhibitors into
the newly diagnosed setting is evidence of a paradigm
shift in GB clinical trial design. Checkpoint inhibitors
and other immunotherapies are a promising new treat-
ment modality for newly diagnosed GB patients, although
carefully designed clinical trials built on the platforms
developed for the recently completed large-scale, multi-
faceted randomized GB clinical trials will facilitate these
efforts. In the case of immunotherapies, special con-
sideration of autoimmune and CNS toxicities will be
required to properly evaluate these treatments.
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